Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
|Live BSE Quotes||Mar 27, 2017 (Close)|
|Price (Rs)690.95||Open (Rs) 704.00||High (Rs) 704.00||Low (Rs) 689.10|
|% Change-1.76||Volume 1,038,091||Value (Rs) 717,916,392||52-Week H/L 854.50 / 572.40|
|Live NSE Quotes||Mar 27, 2017 (Close)|
|Price (Rs)691.20||Open (Rs) 701.00||High (Rs) 703.35||Low (Rs) 689.50|
|% Change-1.80||Volume 1,859,318||Value (Rs) 1,289,122,178||52-Week H/L 854.95 / 571.90|
|EPS (Rs)* 32.04||P/E Ratio (x) 21.56||Market Cap (Rs m) 1,662,945.99||P/BV (x) 5.30|
|*Trailing 12 months earnings, excluding extraordinary / exceptional items.||BSE Sensex | CNX Nifty|
|Sun Pharma Share Price Chart (Rs) - 1 Year|
Quote & Graph
S&P BSE SENSEX
Indian share markets continued to witness selling pressure in the afternoon session amid weak global markets. At the closing bell, the BSE Sensex stood lower by 188 points.
Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.
Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.
Sun Pharma has announced its 1QFY17 results. The company has reported 22.7% YoY growth in sales and a growth of 266% in the net profits. Here is our analysis of the results.
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.More Views on News
The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.
Digital transactions have fallen since December 2016 both in value and volume terms.
Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.
Markets are moving up even after the fed interest rate hike.
PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.More